Close

Aerie Pharma (AERI) PT Raised to $52 at Needham & Company as Roclatan Knocks It Out of the Park

Go back to Aerie Pharma (AERI) PT Raised to $52 at Needham & Company as Roclatan Knocks It Out of the Park

Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results

September 14, 2016 4:01 PM EDT

RoclatanTM Successfully Achieves Primary Efficacy Endpoint in Mercury 1 Study

Conference Call and Webcast Today, September 14, at 5:00 p.m. ET

IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today reported the successful 90-day primary efficacy results of its 12-month Phase 3 Mercury 1 clinical trial for its fixed-dose combination product candidate, RoclatanTM. The study achieved its primary efficacy endpoint demonstrating statistical superiority over each of... More